Results 11 to 20 of about 103,862 (301)

Deubiquitination of FBP1 by USP7 blocks FBP1–DNMT1 interaction and decreases the sensitivity of pancreatic cancer cells to PARP inhibitors

Molecular Oncology, 2022
Poly[ADP‐ribose] polymerase (PARP) inhibitors can block DNA single‐strand damage repair and subsequently increase double‐stranded breaks (DSBs) by reducing the activity of the PARP1 protease and by preventing the PARP1 protein from dissociating from ...
Xiang Cheng, Bin Zhang, Feng Guo, Heshui Wu, Xin Jin   +4 more
doaj   +1 more source

A clinical case of repeat use of PARP inhibitors in a patient with mBRCA-associated ovarian cancer

Сибирский онкологический журнал, 2022
Backgraound. High-grade serous ovarian carcinoma (HGSOC) is the most common type of ovarian cancer. The prevalence of BRCA1/2 germline mutations is the highest in HGSOC.
A. B. Villert, I. A. Kolomiets, Y. A. Fesik, A. A. Ivanova, N. V. Yunusova, О. N. Churuksaeva   +5 more
doaj   +1 more source

Role of PARP Inhibitors in Glioblastoma and Perceiving Challenges as Well as Strategies for Successful Clinical Development

Frontiers in Pharmacology, 2022
Glioblastoma multiform is the most aggressive primary type of brain tumor, representing 54% of all gliomas. The average life span for glioblastoma multiform is around 14–15 months instead of treatment.
Priya Bisht, V. Udaya Kumar, Ruchi Pandey, Ravichandiran Velayutham, Nitesh Kumar   +4 more
doaj   +1 more source

Drug-Induced Interstitial Lung Disease From PARP Inhibitors (Olaparib and Niraparib) for Ovarian Cancer

Annals of Internal Medicine: Clinical Cases, 2023
Poly (ADP-ribose) polymerase (PARP) inhibitors are approved for the treatment of several types of cancers. We report a case of an 80-year-old Japanese woman who developed drug-induced interstitial lung disease (ILD) during treatment with PARP inhibitors (
Hiroshi Sugimoto, Takanori Enomoto, Mamoru Okuno, Naoko Chayahara, Hiroki Morita, Kyosuke Nakata   +5 more
doaj   +1 more source

PARP Inhibitors in Prostate Cancer [PDF]

Anticancer Research, 2021
Treatment of metastatic prostate cancer has evolved significantly over the past decade. Palliative therapy has, historically, consisted of androgen deprivation, chemotherapy and different radiation therapy approaches. More recently, breakthrough therapy with the use of poly-ADP-ribose polymerase (PARP) inhibitors has led to significant improvement in ...
Kabir, Grewal, Kayanaat, Grewal, Imad A, Tabbara   +2 more
openaire   +2 more sources

PARP-1: a critical regulator in radioprotection and radiotherapy-mechanisms, challenges, and therapeutic opportunities

Frontiers in Pharmacology, 2023
Background: Since its discovery, poly (ADP-ribose) polymerase 1 (PARP-1) has been extensively studied due to its regulatory role in numerous biologically crucial pathways.
Wen-Hao Li, Fei Wang, Gui-Yuan Song, Qing-Hua Yu, Rui-Peng Du, Ping Xu, Ping Xu   +6 more
doaj   +1 more source

Perspectives on PARP Inhibitor Combinations for Ovarian Cancer

Frontiers in Oncology, 2021
Poly (ADP-ribose) polymerase (PARP) inhibitors constitute an important treatment option for ovarian cancer nowadays. The magnitude of benefit from PARP inhibitors is influenced by the homologous recombination status, with greater benefit observed in ...
Renata Colombo Bonadio, Renata Colombo Bonadio, Maria del Pilar Estevez-Diz, Maria del Pilar Estevez-Diz   +3 more
doaj   +1 more source

SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers

The Journal of Clinical Investigation, 2022
Poly(ADP-ribose) polymerase inhibitors (PARP inhibitors) have had an increasing role in the treatment of ovarian and breast cancers. PARP inhibitors are selectively active in cells with homologous recombination DNA repair deficiency caused by mutations ...
Zhen Lu, Weiqun Mao, Hailing Yang, Janice M. Santiago-O’Farrill, Philip J. Rask, Jayanta Mondal, Hu Chen, Cristina Ivan, Xiuping Liu, Chang-Gong Liu, Yuanxin Xi, Kenta Masuda, Eli M. Carrami, Meng Chen, Yitao Tang, Lan Pang, David S. Lakomy, George A. Calin, Han Liang, Ahmed A. Ahmed, Hariprasad Vankayalapati, Robert C. Bast Jr.   +21 more
doaj   +1 more source

Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status

Journal of Ovarian Research, 2023
As a kind of gynecological tumor, ovarian cancer is not as common as cervical cancer and breast cancer, but its malignant degree is higher. Despite the increasingly mature treatment of ovarian cancer, the five-year survival rate of patients is still less
Yongsong Wu, Shilin Xu, Shanshan Cheng, Jiani Yang, Yu Wang   +4 more
doaj   +1 more source

The potential role and application of PARP inhibitors in cancer treatment [PDF]

, 2009
Background: Since many anti-cancer agents act by inflicting DNA damage on tumour cells, there is increasing interest in the use of inhibitors of DNA repair to increase the cytotoxicity of these agents.
Chalmers, Anthony J
core   +2 more sources